- Anthony W C Chow (anthony.chow@rbbh-tr.nhs.uk), consultant cardiologist1,
- Rebecca E Lane, research fellow2,
- Martin R Cowie, professor of cardiology3
- 1 Department of Cardiology, Royal Berkshire and Battle Hospital, Reading RG30 1AJ
- 2 Department of Cardiology, St Mary's Hospital, London W2 1NY
- 3 Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London SW3 6LY
- Correspondence to: A W C Chow
- Accepted 16 April 2003
Heart failure is a sizeable problem in elderly populations, and although pharmacological treatment has improved, outcome generally remains poor. New pacing technologies have been developed to treat heart failure, with promising results
Introduction
The prevalence of heart failure in the general population is estimated to be 1-2% and increases rapidly with age.1 In developed countries heart failure is a leading cause of admission to hospital among elderly patients and accounts for 1-2% of healthcare expenditure.2 Although several pharmacological treatments have improved outcome,3–5 the prognosis of patients with heart failure remains poor. Alternative non-pharmacological approaches including cardiac transplantation have been limited by availability of organs, and the use of artificial left ventricular assist devices remains restricted.
Recently, several promising new developments have taken place in pacing technology to treat selected patients with heart failure. These include atrio-biventricular pacing to correct abnormal patterns of left ventricular contraction and implantable cardiac defibrillators for treatment of malignant ventricular arrhythmias. As the scale of the problem becomes apparent new treatments that have been shown to improve morbidity and possibly mortality in patients with chronic heart failure will undoubtedly have a major impact on clinical practice and healthcare resources.
Methods
Sources and search criteria
We systematically searched PubMed for publications on chronic heart failure and biventricular pacing, cardiac resynchronisation, and implantable cardioverter defibrillators for the years 1985-2003.
The heart failure population
In the developed world the underlying cardiac abnormality for most patients with heart failure is impaired left ventricular systolic function due to ischaemic heart disease or idiopathic dilated cardiomyopathy.6 Despite maximal drug treatment many patients still experience symptoms on minimal exertion or even at rest (New York Heart Association class III-IV), and this functional limitation often has a marked impact on their quality of life. Recurrent and prolonged hospital admissions for periods of decompensation of …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: How much of a social media profile can doctors have?
Published 13 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 13 February 2012
Re: Is it unethical for doctors to encourage healthy adults to donate a kidney to a stranger? No
Published 13 February 2012
Re: Report predicts 20 million AIDS orphans in Africa by 2010
Published 13 February 2012
Re: On the impossibility of being expert
Published 13 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012